Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.56 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.51 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.51 |
| ▸ | AHCY | P23526 | 2/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.42 |
| ▸ | AMD1 | P17707 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18026012 | 1.00 | ADORA2A (0.56) | ADORA2AADORA2BDNMT1DNMT3BAHCY | |
| SCHEMBL18026081 | 1.00 | ADORA2A (0.56) | ADORA2AADORA2BDNMT1DNMT3BAHCY | |
| SCHEMBL18026074 | 0.89 | ADORA2A (0.60) | ADORA2AADORA2BDNMT1DNMT3BAHCY | |
| SCHEMBL18026050 | 0.89 | ADORA2A (0.60) | ADORA2AADORA2BDNMT1DNMT3BAHCY | |
| SCHEMBL18026027 | 0.89 | ADORA2A (0.60) | ADORA2AADORA2BDNMT1DNMT3BAHCY | |
| SCHEMBL18026087 | 0.88 | ADORA2B (0.58) | ADORA2AADORA2BDNMT1DNMT3BAHCY | |
| SCHEMBL18026026 | 0.88 | ADORA2B (0.58) | ADORA2AADORA2BDNMT1DNMT3BAHCY | |
| SCHEMBL18026021 | 0.88 | ADORA2B (0.58) | ADORA2AADORA2BDNMT1DNMT3BAHCY | |
| SCHEMBL18026160 | 0.87 | ADORA2A (0.58) | ADORA2AADORA2BDNMT1DNMT3BAHCY | |
| SCHEMBL18026006 | 0.87 | ADORA2A (0.58) | ADORA2AADORA2BDNMT1DNMT3BAHCY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | TYMP, NME1, PNP | ADORA2A 631/4885ADORA2B 1363/4885DNMT1 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.